Co-receptors for HIV-1 entry

Current Opinion in Immunology

Volumn 9, Issue 4, 1997, Pages 551-562

  Moore, John P ^a   Trkola, Alexandra ^a   Dragic, Tatjana ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RECEPTOR;

CELL MEMBRANE; HUMAN IMMUNODEFICIENCY VIRUS 1; REVIEW; TARGET CELL; VIRUS CELL INTERACTION;

EID: 0030793861     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80110-0     Document Type: Article

References (93)

1. D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. of outstanding interest Nat Med. 2:1996;1293-1300 This review summarizes the history of the discovery of the HIV-1 second receptors, and comprehensively lists and discusses all papers published on this subject until about December 1996.
2. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. of special interest Nat Med. 2:1996;1174-1178 Contains everything you always wanted to know about chemokines and their receptors, but were afraid to ask (if you were an HIV researcher already swamped by the HIV literature).
3. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. of special interest Nature. 384:1996;529-534 Reviews, and critically analyzes, the impact that the second receptor and chemokine discoveries of 1996 have already had on the understanding of HIV pathogenesis.
4. Broder CC, Dimitrov DS. HIV and the 7-transmembrane receptors. Pathobiology. 64:1996;171-179.
5. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Evidence of a new acquired cellular immunodeficiency. New Engl J Med. 305:1982;1425-1431.
6. Dalgleish AG, Beverly PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:1984;763-766.
7. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman J-C, Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:1984;767-768.
8. + T cells by a complex of the 110K viral protein and the T4 molecule. Science. 231:1986;382-385.
9. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47:1986;333-348.
10. Sattentau QJ, Weiss RA. The CD4 antigen: physiological ligand and HIV receptor. Cell. 52:1988;631-632.
11. Moore JP, Jameson BA, Weiss RA, Sattentau QJ. The HIV-cell fusion reaction. Bentz J. Viral Fusion Mechanisms. 1993;233-289 CRC Press Inc, Boca Raton, USA.
12. Moore JP, Sweet RW. The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention. Perspect Drug Discovery and Design. 1:1993;235-250.
13. Levy JA, Cheng-Mayer C, Dina D, Luciw PA. AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science. 232:1986;998.
14. Canivet M, Hoffman AD, Hardy D, Sernatinger J, Levy JA. Replication of HIV-1 in a wide variety of animal cells following phenotypic mixing with murine retroviruses. Virology. 178:1990;543-551.
15. Simon JHM, Schockmel GA, Illei P, James W. A rodent cell line permissive for entry and reverse transcription of human immunodeficiency virus type 1 has a pre-integration block to productive infection. J Gen Virol. 75:1994;2615-2623.
16. Lores P, Boucher V, Mackay C, Pla M, Boehmer HV, Jami J, Barré-Sinoussi F, Weill JC. Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 8:1992;2063-2071.
17. Winslow BJ, Trono D. The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol. 67:1993;2349-2354.
18. Ashorn PA, Berger EA, Moss B. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol. 64:1990;2149-2156.
19. Clapham PR, Blanc D, Weiss RA. Specific cell surface requirements for infection of CD4-positive cells by human immunodeficiency virus type 1, type 2 and simian immunodeficiency virus. Virology. 181:1991;703-715.
20. Clapham PR, McKnight A, Weiss RA. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol. 66:1992;3531-3537.
21. McKnight A, Clapham PR, Weiss RA. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology. 201:1994;703-715.
22. Simon JHM, James W. Heterokaryons formed between a rat myeloma and a mouse fibroblast are permissive for entry of HIV. AIDS Res Hum Retroviruses. 10:1994;1609-1612.
23. Talbot SJ, Weiss RA, Schulz TF. Reduced glycosylation of human cell lines increases susceptibility to CD4-independent infection by human immunodeficiency virus type 2 (LAV-2/B). J Virol. 69:1995;3399-3406.
24. Dragic T, Alizon M. Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2. J Virol. 67:1993;2355-2359.
25. Chesebro B, Buller R, Portis J, Wehrly K. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain cells and skin cells. J Virol. 64:1990;215-221.
26. + T-cell lines vs. primary macrophages. Proc Natl Acad Sci USA. 92:1995;9004-9008.
27. Moore JP, Ho DD. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS. 9:1995;S117-S136. (suppl A).
28. + cells.
29. + cells from a subset of individuals multiply exposed to HIV cannot be infected by M-tropic HIV-1 strains in vitro but that the cells are susceptible to T-tropic strains, implying a restriction at the level of viral entry.
30. + T cells is identified as being the α-chemokine receptor fusin (CXCR4), at least for T-tropic strains.
31. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven transmembrane domain receptor involved in fusion and entry of T-cell tropic human immunodeficiency virus type-1 strains. J Virol. 70:1996;6288-6295.
32. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new CC-chemokine receptor gene, CC-CKR5. of special interest Biochemistry. 11:1996;3362-3367 The first description of the CCR5 receptor, describing its properties as a receptor for MIP-1α, MIP-1β and RANTES in addition to publishing its sequence.
33. + T cells from the same individuals over-secrete β-chemokines.
34. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. of special interest Nature. 381:1996;661-666 Identifies CCR5 as an entry co-factor for M-tropic HIV-1 strains in a manner inhibited by β-chemokines, and describes permanent cell lines expressing CCR5, CXCR4 and other CCR-family members.
35. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. of outstanding interest Cell. 86:1996;1135-1148 This paper shows that both CCR5 and CCR3 can function as entry cofactors for M-tropic strains of HIV of genetic subtypes A, B, C and E, the activity of CCR3 being inhibited by its natural ligand, eotaxin. The paper also shows that the HIV-1 V3 loop can be an important determinant of whether HIV-1 uses CCR5 or CXCR4 for entry.
36. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper S, Parmentier M, Collman RG, Doms RW. A dual-tropic, primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. of outstanding interest Cell. 86:1996;1149-1159 Identifies CCR5 as a co-receptor for M-tropic strains, and shows that a clonal virus of unusually broad tropism (HIV-1 89. 6) is able to use fusin (CXCR4), CCR5 and other β-chemokine receptors (CCR2b, CCR3) for entry.
37. + T cells and macrophages.
38. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol. 70:1996;5487-5494.
39. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, Clapham PR. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol. 70:1996;8355-8360.
40. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med. 185:1997;621-628.
41. + T cells from the EU individuals studied by Paxton [29,33] is identified as a homozygous 32 nucleotide deletion (Δ-32) in the CCR5 gene, which leads to the absence of an expressed CCR5 protein. See also [42].
42. + T cells from certain Caucasian individuals to resist infection by M-tropic HIV-1 strains. Individuals homozygous for this defect are estimated to constitute about 1% of the European populations scanned in this study.
43. Zhang L, Huang Y, He T, Cao Y, Ho DD. HIV-1 subtype and second-receptor use. Nature. 383:1996;768.
44. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural allele. of outstanding interest Science. 273:1996;1856-1862 A multi-cohort study that assessed the frequency of individuals homozygous and heterozygous for the Δ-32 CCR5 allele, in both HIV-1 infected and uninfected populations. The homozygous defect is present in about 1% of Caucasians, but is not found in other populations screened, and its presence is strongly associated with protection against HIV-1 infection. Heterozygozity for the Δ-32 CCR5 allele has only a modest protective effect against disease progression. See also [45].
45. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbaksh K, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. of outstanding interest Nat Med. 2:1996;1240-1243 A study conducted simultaneously with [44] that focuses on the Chicago component of the Multicenter AIDS Cohort Study group. This study draws similar conclusions to [44], notably that the homozygous Δ-32 CCR5 allele is strongly associated with protection against HIV-1 infection and that heterozygozity only moderately protects against disease progression.
46. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. of special interest Nat Med. 5:1997;252-253 A note that documents the existence of an HIV-1 infected Δ-32 CCR5 homozygote, while not providing details of the co-receptors used by the infecting HIV-1 strain, or its phenotype.
47. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. of special interest Nature. 384:1996;179-183 This study uses transfected, CCR5-expressing cells and an MIP-1β binding and competition assay to show that gp120 of M-tropic, but not T-tropic, HIV-1 isolates interacts with CCR5. The interaction is induced by soluble CD4, inhibited by anti-gp120 mAbs and is not dependent on sequences within the V1 or V2 loops of gp120. Direct binding of labelled gp120 to CCR5 is also demonstrated. See also [48].
48. + T cells to demonstrate that monomeric and oligomeric gp120 molecules from M-tropic, but not T-tropic, strains of HIV-1 genetic subtypes A, B and E interact with CCR5. CD4 binding is necessary for gp120 to bind to CCR5 with high affinity, and the interaction is inhibited by neutralizing, but not by non-neutralizing, anti-gp120 mAbs.
49. Lapham CK, Ouyang J, Chandrasekhar, Nguyen NY, Dimitrov DS, Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. of special interest Science. 274:1996;602-605 A radioimmunoprecipitation assay is used to identify a complex of T-tropic gp120 with CD4 and CXCR4 in detergent lysates of several cell lines.
50. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. of special interest Nature. 382:1996;829-833 The paper describes the identification of the α-chemokine SDF-1 as the ligand for CXCR4, and shows that SDF-1 can inhibit the entry of TCLA viruses such as IIIB that are known to use this co-receptor. See also [51].
51. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J-L, Arenzana-Seisdedos F, Schwartz O, Heard J-M, Clark-Lewis I, Legler DF, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. of special interest Nature. 382:1996;833-835 An independent, simultaneous demonstration of the same critical observations of SDF-1 and CXCR4 that were made by Bleul [50].
52. Hesselgesser J, Halks-Miller M, Del Vecchio V, Peiper SC, Hoxie J, Kolson DL, Taub D, Horuk R. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol. 7:1997;112-121.
53. Cocchi F, De Vico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med. 2:1996;1244-1247.
54. Oravecz T, Pall M, Norcross MA. β-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol. 157:1996;1329-1332.
55. mac239. J Virol. 71:1997;2522-2527.
56. Chen Z-W, Zhou P, Ho DD, Landau NR, Marx PA. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol. 7:1997;2705-2714.
57. - cells.
58. Reeves JD, Schulz TF. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol. 71:1997;1453-1465.
59. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, Smyth RJ, Collman RG, Broder CC, Vassart G, et al. Regions in β-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell. 87:1996;437-446.
60. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA. Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science. 274:1996;1924-1926.
61. Bieniasz PD, Fridell RA, Aramori I, Ferguson SSG, Caron MG, Cullen BR. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J. 16:1997;2599-2609.
62. Edinger AL, Amedee A, Miller K, Doranz BJ, Endres M, Sharron M, Samson M, Lu Z-H, Clements JE, Murphey-Corb M, et al. Differential utilization of CCR5 by macrophage and T-cell tropic SIV strains. Proc Natl Acad Sci USA. 94:1997;4005-4010.
63. Wieder KJ, Chatis P, Boltax J, Wieder I, Nuovo G, Strom TB. Human immunodeficiency virus type 1 entry into murine cell lines and lymphocytes from transgenic mice expressing a glycoprotein 120-binding mutant mouse CD4. AIDS Res Hum Retroviruses. 12:1996;867-876.
64. + T-lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. of special interest J Virol. 70:1996;8758-8764 Macrophages from individuals with a homozygous Δ-32 CCR5 allele resist infection with M-tropic strains of HIV-1 that are able to replicate in macrophages from individuals with wild-type CCR5 alleles, implicating CCR5 as the most important co-receptor for HIV-1 entry into these cells.
65. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, Yi Y, Turner J, Guo H-H, Du J-G, Peiper SC, et al. Role of CCR5 in infection of primary macrophages and lymphocytes by M-tropic strains of HIV: resistance to patient-derived and prototype isolates resulting from the Δccr5 mutation. in press J Virol. 1997.
66. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 385:1997;645-649.
67. Cheng-Mayer C, Liu R, Landau NR, Stomatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 co-receptor. J Virol. 71:1997;1657-1661.
68. Dittmar MT, McKnight, Simmons G, Clapham PR, Weiss RA, Simmonds P. HIV-1 tropism and co-receptor use. Nature. 385:1997;495-496.
69. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA, Clapham PR. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol. 71:1997;1692-1696.
70. Kozak SL, Platt EJ, Madani N, Ferro FE Jr, Peden K, Kabat D. CD4, CXCR-4 and CCR-5 dependencies for infection by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. of outstanding interest J Virol. 71:1997;873-882 Studies how CD4 dependency affects the ability of primary and TCLA strains to use CCR5 (low CD4 dependency) and CXCR4 (efficiency of its use is proportional to the CD4 concentration), and so makes important contributions to understanding how these receptors function in different cell contexts.
71. Platt EJ, Madiani N, Kozak SL, Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol. 71:1997;883-890.
72. + T-cell-derived factor(s), but not β-chemokines RANTES, MIP-1α, and MIP-1β, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA. 93:1996;15341-15345.
73. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature. 382:1996;767.
74. Canque B, Rosenzwajg A, Gey A, Tartour E, Fridman WH, Gluckman JC. Macrophage inflammatory protein-1α is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood. 87:1996;2011-2019.
75. Granelli-Piperno A, Moser B, Pope M, Chen D, Wei Y, Isdell F, O'Doherty U, Paxton W, Koup R, Mojsov S, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med. 184:1996;2433-2438.
76. Willett BJ, Hosie MJ, Neil JC, Turner JD, Hoxie JA. Common mechanism of infection by lentiviruses. Nature. 385:1997;587.
77. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med. 184:1996;569-578.
78. Moore JP, Koup RA. Chemoattractants attract HIV researchers. J Exp Med. 184:1996;311-313.
79. Moore JP. Co-receptors: implications for HIV pathogenesis and therapy. Science. 276:1997;51-52.
80. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. in press Proc Natl Acad Sci USA. 1997.
81. Zolla-Pazner S, Sharpe S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res Hum Retroviruses. 11:1995;1449-1458.
82. Zhou JY, Montefiori DC. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J Virol. 71:1997;2512-2517.
83. + T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science. 160:1993;689-692.
84. Arenzana-Seisedos F, Virelizier J-L, Rousset D, Clark-Lewis I, Loetscher P, Moser B, Baggiolini M. HIV blocked by chemokine antagonist. of special interest Nature. 383:1996;400 A derivative of RANTES that lacks eight residues from its amino terminus acts as a RANTES antagonist, prevents HIV-1 entry, yet lacks chemotactic activity in vitro.
85. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H. Sensitivity to inhibition by β-chemokines correlates with biological phenotypes of primary HIV-1 isolates. of special interest Proc Natl Acad Sci USA. 93:1996;15382-15387 Primary NSI strains tend to be sensitive to β-chemokines, primary SI strains insensitive, β-chemokine sensitivity correlates with the V3 sequence changes associated with phenotypic switches. Of note is that NSI strains from AIDS patients are still sensitive to β-chemokines, indicating that disease progression is not due to escape from β-chemokine inhibition.
86. + T cells of HIV-1 infected and uninfected people, irrespective of their state of disease progression.
87. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S-I, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:1996;635-638.
88. Ugolini S, Moulard M, Mondor I, Barois N, Demandolx D, Hoxie J, Brelot A, Alizon M, Davoust J, Sattentau QJ. HIV-1 gp120 from T cell line tropic viruses induces an association between CD4 and the chemokine receptor CXCR4. J Immunol. 1997;. in press.
89. Lu Z-H, Berson JF, Chen Y-H, Turner JD, Zhang T-Y, Sharron M, Jenks MH, Wang Z-X, Kim J, Rucker J, Hoxie JA, Peiper SC, Doms RW. Evolution of HIV-1 co-receptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA. 94:1997;6426-6431.
90. Doranz BJ, Lu Z-H, Rucker J, Zhang T-J, Sharron M, Cen Y-H, Wang Z-X, Guo H-H, Du J-G, Accavitti MA, Doms RW, Peiper SC. Structural determinants of CCR5 coreceptor function for HIV-1. J Virol. 1997;. in press.
91. Long D, Berson JF, Yi Y, Hoffman TL, Endres MJ, Broder CC, Lambert DM, Hopkins S, Collman RG, Doms RW. Galactosylceramide-dependent entry of human immunodeficiency virus type-1 is independent of CXCR4 and CCR5. J Virol. 1997;. in press.
92. + T cells by M-tropic strains. Demonstrates that CCR5 levels on activated T cells vary significantly between individuals, and that there is a correlation between CCR5 expression and the infectability of the cells by M-tropic strains.
93. Trkola A, Paxton WA, Monard SP, Hoxie JA, Siani MA, Thompson DA, Wu L, Mackay CR, Horuk R, Moore JP. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC- and CXC-chemokines. J Virol. 1997;. in press.